CN108699149B - 抗-ror1抗体及其用途 - Google Patents

抗-ror1抗体及其用途 Download PDF

Info

Publication number
CN108699149B
CN108699149B CN201780009313.5A CN201780009313A CN108699149B CN 108699149 B CN108699149 B CN 108699149B CN 201780009313 A CN201780009313 A CN 201780009313A CN 108699149 B CN108699149 B CN 108699149B
Authority
CN
China
Prior art keywords
ror1
binding protein
binding
sample
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780009313.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN108699149A (zh
Inventor
阿什维尼·巴拉克里什南
本杰明·G·霍夫斯特伦
朱莉·伦道夫-哈贝克
斯坦利·R·瑞德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of CN108699149A publication Critical patent/CN108699149A/zh
Application granted granted Critical
Publication of CN108699149B publication Critical patent/CN108699149B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201780009313.5A 2016-02-02 2017-02-02 抗-ror1抗体及其用途 Active CN108699149B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662290337P 2016-02-02 2016-02-02
US62/290,337 2016-02-02
US201662324876P 2016-04-19 2016-04-19
US62/324,876 2016-04-19
PCT/US2017/016300 WO2017136607A1 (en) 2016-02-02 2017-02-02 Anti-ror1 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
CN108699149A CN108699149A (zh) 2018-10-23
CN108699149B true CN108699149B (zh) 2023-01-06

Family

ID=58054529

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780009313.5A Active CN108699149B (zh) 2016-02-02 2017-02-02 抗-ror1抗体及其用途

Country Status (9)

Country Link
US (3) US10968275B2 (https=)
EP (2) EP4006056A1 (https=)
JP (2) JP7029401B2 (https=)
CN (1) CN108699149B (https=)
AU (1) AU2017213844A1 (https=)
CA (1) CA3012827A1 (https=)
ES (1) ES2903228T3 (https=)
MX (1) MX2018009011A (https=)
WO (1) WO2017136607A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6865688B2 (ja) 2015-01-16 2021-04-28 ジュノー セラピューティクス インコーポレイテッド Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体
EA201891066A1 (ru) 2015-10-30 2018-10-31 ЭнБиИ-ТЕРАПЬЮТИКС АГ Антитела к ror1
SG11201806120WA (en) 2016-01-20 2018-08-30 Scripps Research Inst Ror1 antibody compositions and related methods
CN108699149B (zh) 2016-02-02 2023-01-06 弗雷德哈钦森癌症中心 抗-ror1抗体及其用途
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3665193A1 (en) 2017-08-07 2020-06-17 NBE Therapeutics AG Anthracycline-based antibody drug conjugates having high in vivo tolerability
JP7447006B2 (ja) 2017-11-01 2024-03-11 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
SG11202003427XA (en) 2017-11-06 2020-05-28 Juno Therapeutics Inc Combination of a cell therapy and a gamma secretase inhibitor
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
WO2020143506A1 (zh) * 2019-01-08 2020-07-16 深圳大学 检测多种恶性肿瘤细胞的抗体及其应用
CA3123303A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
TW202320858A (zh) 2021-07-19 2023-06-01 美商薩諾管理公司 免疫接合物及方法
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法
WO2023186100A1 (zh) * 2022-04-02 2023-10-05 山东先声生物制药有限公司 抗ror1的抗体及其用途
IL318546A (en) * 2022-07-26 2025-03-01 Aimed Bio Inc Anti-ROR1 antibody and its uses
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
CN115724973B (zh) * 2022-09-26 2023-07-11 普健生物（武汉）科技有限公司 抗人ror1高亲和力兔单克隆抗体及其应用
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024140641A1 (zh) * 2022-12-27 2024-07-04 上海医药集团生物治疗技术有限公司 靶向ror1的抗原结合蛋白
CN115894691B (zh) * 2022-12-27 2026-03-03 上海医药集团生物治疗技术有限公司 靶向ror1的抗原结合蛋白
CN116183472B (zh) * 2023-04-25 2023-08-18 上海益诺思生物技术股份有限公司 Cba法检测非人类灵长类动物细胞因子的验证方法
WO2025007910A1 (en) * 2023-07-04 2025-01-09 TJ Biopharma (Shanghai) Co., Ltd. Anti-ror1 antibodies and uses thereof
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA114536A (en) 1908-09-18 1908-10-13 Adolphe Chalas Nickel recovering process
CA138293A (en) 1911-11-06 1912-02-06 Charles E. Archie Variable speed gearing
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
CA2480052A1 (en) 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
WO2005035732A2 (en) 2003-02-19 2005-04-21 Dyax Corporation Papp-a ligands
WO2005037235A2 (en) 2003-10-16 2005-04-28 Imclone Systems Incorporated Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
US7973139B2 (en) 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
BRPI0910509B8 (pt) 2008-07-10 2021-05-25 Toray Industries uso do anticorpo, anticorpo e composição farmacêutica
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2010124188A1 (en) 2009-04-23 2010-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US9242014B2 (en) 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
US9163258B2 (en) 2010-07-23 2015-10-20 Fred Hutchinson Cancer Research Center Method for the treatment of obesity
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
US9758586B2 (en) 2010-12-01 2017-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ROR1 antibodies
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
CN110200997A (zh) 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
AU2012294431B2 (en) 2011-08-09 2017-03-30 Athera Biotechnologies Ab Antibodies binding to phosphorylcholine (PC) and/or PC conjugates
SG11201400859SA (en) 2011-09-22 2014-04-28 Amgen Inc Cd27l antigen binding proteins
CA2881981A1 (en) 2012-08-20 2014-02-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
EP2968601A1 (en) 2013-03-10 2016-01-20 Baylor College Of Medicine Chemotherapy-resistant immune cells
KR102048855B1 (ko) 2014-07-29 2019-11-26 셀렉티스 암 면역요법을 위한 ror1(ntrkr1) 특이적 키메라 항원 수용체
MX389823B (es) 2014-10-27 2025-03-20 Fred Hutchinson Cancer Center Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
JP6865688B2 (ja) 2015-01-16 2021-04-28 ジュノー セラピューティクス インコーポレイテッド Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体
CN108137669B (zh) 2015-05-18 2023-02-17 优瑞科生物技术公司 抗ror1嵌合抗原受体
CN108699149B (zh) 2016-02-02 2023-01-06 弗雷德哈钦森癌症中心 抗-ror1抗体及其用途
MA45341A (fr) 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy;Amir H. DaneshManesh 等;《Int. J. Cancer》;20080610;第123卷;第1190-1195页 *
Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies;Jiahui Yang 等;《PLOS ONE》;20110630;第6卷(第6期);第1-15页 *

Also Published As

Publication number Publication date
CN108699149A (zh) 2018-10-23
WO2017136607A1 (en) 2017-08-10
US20210147540A1 (en) 2021-05-20
JP2022028918A (ja) 2022-02-16
EP4006056A1 (en) 2022-06-01
MX2018009011A (es) 2018-11-19
US11932691B2 (en) 2024-03-19
US20240352119A1 (en) 2024-10-24
AU2017213844A1 (en) 2018-08-02
EP3411408B1 (en) 2021-12-08
ES2903228T3 (es) 2022-03-31
JP7029401B2 (ja) 2022-03-03
EP3411408A1 (en) 2018-12-12
US10968275B2 (en) 2021-04-06
CA3012827A1 (en) 2017-08-10
US20190040132A1 (en) 2019-02-07
JP2019511904A (ja) 2019-05-09

Similar Documents

Publication Publication Date Title
US20240352119A1 (en) Anti-ror1 antibodies and uses thereof
US11155632B2 (en) Anti-CD47 monoclonal antibody and use thereof
CN108373504B (zh) Cd24特异性抗体和抗cd24-car-t细胞
JP2022130393A (ja) 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用
US12492252B2 (en) Anti-GPC3 antibody, anti-GPC3 chimeric antigen receptor and GPC3/CD3 bispecific antibody
CN113004408B (zh) 抗人程序死亡因子-1单克隆抗体
CN109970859B (zh) Glypican-3特异性抗体及其特异性CAR-T细胞
JP2022547850A (ja) 抗ｔｉｇｉｔ免疫阻害剤及び応用
CN111454358A (zh) 一种嵌合抗原受体及其应用
EP4303234A1 (en) Antibody against nkp46 and application of antibody
CN117529337A (zh) 针对dll3的结合分子及其应用
WO2022099126A1 (en) Anti-psma antibodies and methods of use
HK40075786A (en) Anti-ror1 antibodies and uses thereof
HK40000385B (en) Anti-ror1 antibodies and uses thereof
EP4328243A1 (en) Asymmetric antibody with improved cytotoxicity against cancer cell
JP7209284B2 (ja) Ｔｍｅｍ１３２ａに結合する抗体、抗がん剤、およびがんの検査方法
HK40048285A (en) Anti-human program death factor-1 monoclonal antibody
HK40048285B (en) Anti-human program death factor-1 monoclonal antibody
WO2022213050A1 (en) Il-38-specific antibodies
CN119176882A (zh) 一种双靶向bcma/gprc5d的嵌合分子受体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Washington State

Applicant after: Fred Hutchinson Cancer Center

Address before: Washington State

Applicant before: Seattle Cancer Care Alliance

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220927

Address after: Washington State

Applicant after: Seattle Cancer Care Alliance

Address before: Washington State

Applicant before: FRED HUTCHINSON CANCER RESEARCH CENTER

GR01 Patent grant
GR01 Patent grant